Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy

Loading news article.

Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy | WAPE

Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy

Article summary

Related companies

Comments —